S&P 500   3,662.45 (+1.13%)
DOW   29,823.92 (+0.63%)
QQQ   303.91 (+1.43%)
AAPL   122.80 (+3.15%)
MSFT   216.20 (+1.00%)
FB   286.50 (+3.44%)
GOOGL   1,796.09 (+2.38%)
AMZN   3,222.60 (+1.72%)
TSLA   585.14 (+3.09%)
NVDA   535.72 (-0.06%)
BABA   264.00 (+0.24%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.60 (-0.06%)
T   28.89 (+0.49%)
NIO   45.31 (-10.33%)
F   9.23 (+1.65%)
ACB   9.90 (-15.24%)
NFLX   504.78 (+2.87%)
BA   213.28 (+1.22%)
GILD   61.11 (+0.73%)
DIS   149.09 (+0.73%)
S&P 500   3,662.45 (+1.13%)
DOW   29,823.92 (+0.63%)
QQQ   303.91 (+1.43%)
AAPL   122.80 (+3.15%)
MSFT   216.20 (+1.00%)
FB   286.50 (+3.44%)
GOOGL   1,796.09 (+2.38%)
AMZN   3,222.60 (+1.72%)
TSLA   585.14 (+3.09%)
NVDA   535.72 (-0.06%)
BABA   264.00 (+0.24%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.60 (-0.06%)
T   28.89 (+0.49%)
NIO   45.31 (-10.33%)
F   9.23 (+1.65%)
ACB   9.90 (-15.24%)
NFLX   504.78 (+2.87%)
BA   213.28 (+1.22%)
GILD   61.11 (+0.73%)
DIS   149.09 (+0.73%)
S&P 500   3,662.45 (+1.13%)
DOW   29,823.92 (+0.63%)
QQQ   303.91 (+1.43%)
AAPL   122.80 (+3.15%)
MSFT   216.20 (+1.00%)
FB   286.50 (+3.44%)
GOOGL   1,796.09 (+2.38%)
AMZN   3,222.60 (+1.72%)
TSLA   585.14 (+3.09%)
NVDA   535.72 (-0.06%)
BABA   264.00 (+0.24%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.60 (-0.06%)
T   28.89 (+0.49%)
NIO   45.31 (-10.33%)
F   9.23 (+1.65%)
ACB   9.90 (-15.24%)
NFLX   504.78 (+2.87%)
BA   213.28 (+1.22%)
GILD   61.11 (+0.73%)
DIS   149.09 (+0.73%)
S&P 500   3,662.45 (+1.13%)
DOW   29,823.92 (+0.63%)
QQQ   303.91 (+1.43%)
AAPL   122.80 (+3.15%)
MSFT   216.20 (+1.00%)
FB   286.50 (+3.44%)
GOOGL   1,796.09 (+2.38%)
AMZN   3,222.60 (+1.72%)
TSLA   585.14 (+3.09%)
NVDA   535.72 (-0.06%)
BABA   264.00 (+0.24%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.60 (-0.06%)
T   28.89 (+0.49%)
NIO   45.31 (-10.33%)
F   9.23 (+1.65%)
ACB   9.90 (-15.24%)
NFLX   504.78 (+2.87%)
BA   213.28 (+1.22%)
GILD   61.11 (+0.73%)
DIS   149.09 (+0.73%)
Log in
NASDAQ:VBIV

VBI Vaccines Stock Forecast, Price & News

$3.16
-0.26 (-7.60 %)
(As of 12/1/2020 03:59 PM ET)
Add
Compare
Today's Range
$3.13
Now: $3.16
$3.63
50-Day Range
$2.15
MA: $2.62
$3.07
52-Week Range
$0.69
Now: $3.16
$6.93
Volume554,686 shs
Average Volume9.58 million shs
Market Capitalization$764.89 million
P/E RatioN/A
Dividend YieldN/A
Beta1.93
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the target virus to elicit a potent immune response. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. In addition, the company engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It primarily serves physicians and pharmacists through direct sales. VBI Vaccines Inc. has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. It also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
VBI Vaccines logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.6Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VBIV
CUSIPN/A
Phone617-830-3031
Employees123

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.22 million
Book Value$0.50 per share

Profitability

Net Income$-54,810,000.00
Net Margins-2,467.47%

Miscellaneous

Market Cap$764.89 million
Next Earnings Date3/4/2021 (Estimated)
OptionableOptionable
$3.16
-0.26 (-7.60 %)
(As of 12/1/2020 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VBIV News and Ratings via Email

Sign-up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











VBI Vaccines (NASDAQ:VBIV) Frequently Asked Questions

How has VBI Vaccines' stock price been impacted by Coronavirus (COVID-19)?

VBI Vaccines' stock was trading at $0.9171 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VBIV stock has increased by 245.7% and is now trading at $3.17.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of VBI Vaccines?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for VBI Vaccines
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than VBI Vaccines?

Wall Street analysts have given VBI Vaccines a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but VBI Vaccines wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is VBI Vaccines' next earnings date?

VBI Vaccines is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for VBI Vaccines
.

How were VBI Vaccines' earnings last quarter?

VBI Vaccines Inc. (NASDAQ:VBIV) posted its quarterly earnings results on Monday, November, 2nd. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.01. VBI Vaccines had a negative return on equity of 46.47% and a negative net margin of 2,467.47%.
View VBI Vaccines' earnings history
.

What price target have analysts set for VBIV?

4 brokers have issued 1 year target prices for VBI Vaccines' shares. Their forecasts range from $4.00 to $9.00. On average, they expect VBI Vaccines' share price to reach $6.25 in the next year. This suggests a possible upside of 97.2% from the stock's current price.
View analysts' price targets for VBI Vaccines
.

Who are some of VBI Vaccines' key competitors?

What other stocks do shareholders of VBI Vaccines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include Canaccord Genuity (), BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird () and Wellington Shields ().

Who are VBI Vaccines' key executives?

VBI Vaccines' management team includes the following people:
  • Mr. Jeffrey R. Baxter F.C.M.A., FCMA, Pres, CEO & Director (Age 59, Pay $736.13k)
  • Dr. David Evander Anderson, Chief Scientific Officer (Age 50, Pay $452.7k)
  • Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D., Chief Medical Officer (Age 65, Pay $488.2k)
  • Mr. Christopher McNulty, CFO, Head of Bus. Devel. & Director (Age 43)
  • Nicole Anderson, Director of Corp. Communications & Investor Relations
  • Ms. Athena Kartsaklis, Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer (Age 55)
  • Ms. Nell Beattie, Chief Bus. Officer (Age 32)
  • Mr. Avi Mazaltov, Global Head of Manufacturing & GM of SciVac (Age 58)
  • Mr. Misha Nossov, Sr. VP of Market Access & Commercial
  • Mr. T. Adam Buckley, Sr. VP of Bus. Devel. (Age 44)

What is VBI Vaccines' stock symbol?

VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."

Who are VBI Vaccines' major shareholders?

VBI Vaccines' stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (7.67%), BlackRock Inc. (5.05%), Cambridge Investment Research Advisors Inc. (0.79%), Charles Schwab Investment Management Inc. (0.55%), General American Investors Co. Inc. (0.43%) and Thrivent Financial for Lutherans (0.21%). Company insiders that own VBI Vaccines stock include Christopher Mcnulty, Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Perceptive Advisors Llc, Steven Gillis and Tomer Kariv.
View institutional ownership trends for VBI Vaccines
.

Which major investors are selling VBI Vaccines stock?

VBIV stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Dupont Capital Management Corp, First Midwest Bank Trust Division, General American Investors Co. Inc., Morgan Stanley, Federated Hermes Inc., JPMorgan Chase & Co., and Wells Fargo & Company MN.
View insider buying and selling activity for VBI Vaccines
.

Which major investors are buying VBI Vaccines stock?

VBIV stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Charles Schwab Investment Management Inc., Thrivent Financial for Lutherans, Squarepoint Ops LLC, SG Americas Securities LLC, Cambridge Investment Research Advisors Inc., Raymond James Financial Services Advisors Inc., and AQR Capital Management LLC. Company insiders that have bought VBI Vaccines stock in the last two years include Christopher Mcnulty, Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Perceptive Advisors Llc, Steven Gillis, and Tomer Kariv.
View insider buying and selling activity for VBI Vaccines
.

How do I buy shares of VBI Vaccines?

Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is VBI Vaccines' stock price today?

One share of VBIV stock can currently be purchased for approximately $3.17.

How big of a company is VBI Vaccines?

VBI Vaccines has a market capitalization of $767.31 million and generates $2.22 million in revenue each year. The biopharmaceutical company earns $-54,810,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. VBI Vaccines employs 123 workers across the globe.

What is VBI Vaccines' official website?

The official website for VBI Vaccines is www.vbivaccines.com.

How can I contact VBI Vaccines?

VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at 617-830-3031 or via email at [email protected]

This page was last updated on 12/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.